A 63-Year-Old Man with Myelofibrosis : Episode 5
Pacritinib for Patients With Myelofibrosis
Stephen T. Oh, MD, PhD, discusses patients who would be suitable to receive pacritinib for myelofibrosis, highlighting data showing correlation between transfusion independence and reduction in bone marrow reticulin fibrosis.
EP: 1.Patient Profile: A 63-Year-Old Man with Myelofibrosis
EP: 2.Determining and Addressing Ruxolitinib Failure in Myelofibrosis
EP: 3.Treatment Sequencing in Myelofibrosis
EP: 4.Monitoring Therapeutic Response in Patients With Myelofibrosis
Now Viewing
EP: 5.Pacritinib for Patients With Myelofibrosis
EP: 6.Balancing Toxicity Concerns with Achieving Adequate Response in Myelofibrosis
EP: 7.Emerging JAK Inhibitors for Patients With Myelofibrosis
EP: 8.Perspectives on the Future on Myelofibrosis Treatment
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
- A 63-year-old man recently diagnosed with primary MF and initiated on 10 mg BID ruxolitinib.
- PMH: type 2 diabetes, hypercholesteremia, and hypertension, squamous cell carcinoma (SCC)
Follow up and Clinical Workup at 3 Months:
- Exam: night sweats improved.
- Labs: Hb 7.8 g/dL; Plt 80 x 109/L (previously 135k) stabilized.
- Some spleen reduction.
- Patient receives ~1 unit RBC per month.
Follow up and Clinical Workup at 6 Months:
- Patient reports complaints of fatigue and abdominal pain.
- Labs: Plt 55 x 109/L; Hgb 6.8 g/dL
- Patient now receives 2 units RBC per month.
- Experienced recurrence of SCC.
Related Videos
Related Content
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024Article
During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
